Neuromuscular blocking agents

109
NEUROMUSCULAR BLOCKING AGENTS PRESENTED BY: DR.JAGADISH JENA DEPT.OF ANAEST.& CR.CARE VIMSAR,BURLA

Transcript of Neuromuscular blocking agents

Page 1: Neuromuscular blocking agents

NEUROMUSCULAR BLOCKING AGENTS

PRESENTED BY: DR.JAGADISH JENA DEPT.OF ANAEST.& CR.CARE VIMSAR,BURLA

Page 2: Neuromuscular blocking agents

HISTORY

Page 3: Neuromuscular blocking agents
Page 4: Neuromuscular blocking agents

Definition: NMBA are the drugs that act peripherally at NM-Junction and muscle fiber itself to block neuromuscular transmission.

Why do we need them ? In order to facilitate muscle relaxation for surgery

and mechanical ventilation during surgery & in ICU.

Page 5: Neuromuscular blocking agents
Page 6: Neuromuscular blocking agents

Neuromuscular junction

• Association between a motor neuron and a muscle cell.• Synaptic cleft.:Synaptic cleft.:The cell membranes of the neuron and

muscle fiber are separated by a narrow (20-nm) gap.• The neurotransmitter responsible for neurotransmission

at the neuromuscular junction is acetylcholine.• It is synthesized in the cytoplasm by combination of

choline and coenzyme A with the help of choline acetyl transferase.

• These synthesized acetylcholine stored in vesicles.• A single vesicle contains about a quantum of Ach .

Page 7: Neuromuscular blocking agents

• As a nerve’s action potential depolarizes its terminal, an influx of calcium ions through voltage-gated calcium channels into the nerve cytoplasm allows storage vesicles to fuse with the terminal plasma membrane and release their contents.• The ACh molecules diffuse across the synaptic cleft to bind

with nicotinic cholinergic receptors on a specialized portion of the muscle membrane at the motor end-plate.

• Each neuromuscular junction contains approximately 5 million of these receptors.

• Among these minimum 500000 receptors required to be activated for normal muscle contraction.

Page 8: Neuromuscular blocking agents

Structure of ACh receptors• Each ACh receptor in the neuromuscular junction normally consists of five protein subunits; two α subunits; and single β, δ, and ε subunits. • Only the two identical α subunits are capable of binding

Ach molecules.• If both binding sites are occupied byACh, a conformational change in the subunits, briefly(1 ms) opens an ion channel in the core of the receptor.• The channel will not open if Ach binds on only one site.

Page 9: Neuromuscular blocking agents
Page 10: Neuromuscular blocking agents

• Another isoform of Ach contains a γ subunit instead of the ε subunit known as fetal or imature receptor,because this form initially expressed in fetal muscle.

• It is also often referred to as extrajunctional receptors.

Cations flow through the open ACh receptor channel (sodium and calcium in; potassium out), generating an end-plate potential .• When enough receptors are occupied by ACh, the end- plate potential will be sufficiently strong to depolarize the perijunctional membrane.

Page 11: Neuromuscular blocking agents

• Sodium channels are present in muscle membrane.• Perijunctional areas of muscle membrane have a higher

density of these sodium channels than other parts of the membrane.

• These sodium channels have two types of gate - voltage dependent - time dependent• Sodium ions pass only when both gates are open.

Page 12: Neuromuscular blocking agents

sodium channesodium channel is a transmembrane protein that can be conceptualized as having two gates. two gates.

Sodium ions pass only when both gates are open.

Opening of the gates is Opening of the gates is time dependent and time dependent and voltage dependentvoltage dependent.

The channel therefore possesses three three functional states.functional states.

A...At rest.At rest, the lower gate is open but the upper gate

is closed B...reaches threshold

voltage depolarization,depolarization, the upper gate opens and

sodium can pass C...Shortly after the upper

gate opens the timedependent lower timedependent lower

gate closesgate closes

Page 13: Neuromuscular blocking agents

• With the opening of sodium channels and entry of sodium,calcium ions release from sarcoplasmic reticulum.

• This intracellular calcium allows the contractile proteins actin and myosin to interact, bringing about muscle contraction.

Page 14: Neuromuscular blocking agents

Steps in normal NM transmission.

Page 15: Neuromuscular blocking agents
Page 16: Neuromuscular blocking agents

Classification-mechanism & duration of action

Depolarizing Nondepolarizing

Page 17: Neuromuscular blocking agents

MECHANISM OF ACTION of depolarizing NMBA

Page 18: Neuromuscular blocking agents

Phases of block in Depolarizing NMBA

Page 19: Neuromuscular blocking agents

Mechanism of action of non-depolarizing NMBA

Page 20: Neuromuscular blocking agents

OTHER MECHANISMS OF NEUROMUSCULAR

BLOCKADE

Page 21: Neuromuscular blocking agents
Page 22: Neuromuscular blocking agents
Page 23: Neuromuscular blocking agents
Page 24: Neuromuscular blocking agents

SEQUENCE OF MUSCLE BLOCKADE

• First muscle to be blocked by both depolarising and non depolarizng muscle relaxants are the central muscles then peripheral muscles blocked.

• So the sequence of blockade is... FACE – JAW –PHARYNX-LARYNX –

RESPIRATORY –TRUNK MUSCLES – LIMB MUSCLES

• At recovery these recover in the same order.

Page 25: Neuromuscular blocking agents

Depolarizing NMBA

(Suxamethonium)

Page 26: Neuromuscular blocking agents

SUCCINYLCHOLINE

Page 27: Neuromuscular blocking agents
Page 28: Neuromuscular blocking agents

Mechanism of action

Page 29: Neuromuscular blocking agents

Metabolism & Excretion

Page 30: Neuromuscular blocking agents

• However duration of action can be prolonged or prolonged apnea after succinylcholine can occur due to the following conditions:

- low pseudocholinesterase - atypical pseudocholinesterase - high dose or phase 2 block - hypothermia

Page 31: Neuromuscular blocking agents

Decreased level of pseudocholinesterase

Page 32: Neuromuscular blocking agents

Atypical/Abnormal pseudocholinesterse

Page 33: Neuromuscular blocking agents

Measurement of Atypical Pseudocholinesterse

Page 34: Neuromuscular blocking agents

Dibucaine Number

Page 35: Neuromuscular blocking agents

Management of succinylcholine Apnoea

Page 36: Neuromuscular blocking agents
Page 37: Neuromuscular blocking agents

Drug interaction special considerations

Page 38: Neuromuscular blocking agents

2. Nondepolarizing Relaxants

Page 39: Neuromuscular blocking agents

Drug Interactions

Page 40: Neuromuscular blocking agents

Dosage & Storage

Page 41: Neuromuscular blocking agents
Page 42: Neuromuscular blocking agents

Side Effects & Clinical Considerations

Page 43: Neuromuscular blocking agents

1.Cardiovascular

Page 44: Neuromuscular blocking agents
Page 45: Neuromuscular blocking agents
Page 46: Neuromuscular blocking agents

B. Fasciculations

Page 47: Neuromuscular blocking agents

C. Hyperkalemia

Page 48: Neuromuscular blocking agents

Conditions causing susceptibility to succinylcholine-induced

hyperkalemia

Page 49: Neuromuscular blocking agents

Mechanism of hyperkalemia

Page 50: Neuromuscular blocking agents
Page 51: Neuromuscular blocking agents

D. Muscle Pains

Page 52: Neuromuscular blocking agents

E. Intragastric Pressure Elevation

Page 53: Neuromuscular blocking agents

F. Intraocular Pressure Elevation

Page 54: Neuromuscular blocking agents

G. Masseter Muscle Rigidity

Page 55: Neuromuscular blocking agents

H. Malignant Hyperthermia

Page 56: Neuromuscular blocking agents

I. Intracranial Pressure

Page 57: Neuromuscular blocking agents
Page 58: Neuromuscular blocking agents

Nondepolarizing Muscle Relaxants

Page 59: Neuromuscular blocking agents

Classification- Chemistry

Gantacurium

Page 60: Neuromuscular blocking agents
Page 61: Neuromuscular blocking agents

Unique Pharmacological Characteristics

Page 62: Neuromuscular blocking agents

A. Suitability for Intubation

Page 63: Neuromuscular blocking agents

Why potent NMBA has slow onset of action? What is priming dose ?

Page 64: Neuromuscular blocking agents

B. Suitability for Preventing Fasciculations

Page 65: Neuromuscular blocking agents

C. Maintenance Relaxation

Page 66: Neuromuscular blocking agents

D. Potentiation by Inhalational Anesthetics

Page 67: Neuromuscular blocking agents

E. Autonomic Side Effects

Page 68: Neuromuscular blocking agents

F. Histamine Release

Page 69: Neuromuscular blocking agents
Page 70: Neuromuscular blocking agents

General Pharmacological Characteristics of Non depolarizing NMBA

Page 71: Neuromuscular blocking agents

A. Temperature• Hypothermia prolongs blockade by • 1.decreasing metabolism

• (eg, mivacurium, atracurium, and cisatracurium) and

• 2.delaying excretion • (eg, pancuronium and vecuronium).

Page 72: Neuromuscular blocking agents

B. Acid–Base Balance• Respiratory acidosis potentiates the

blockade of most nondepolarizing relaxants and antagonizes its reversal.

Page 73: Neuromuscular blocking agents

C. Electrolyte Abnormalities

• Hypokalemia and hypocalcemia ....augment a nondepolarizing block.

• Hypermagnesemia..... potentiates a nondepolarizing blockade by competing with calcium at the motor end-plate.

Page 74: Neuromuscular blocking agents

D.Drug interactions

Page 75: Neuromuscular blocking agents

F. Concurrent Disease• Neurological or muscular disease can have profound

effects on an individual’s response to muscle relaxants.

• Cirrhotic liver disease and chronic renal failure increased volume of distribution and a lower plasma

concentration for a given dose of water-soluble drugs, such as muscle relaxants

• Drugs dependent on hepatic or renal excretion may demonstrate prolonged clearance

• So greater initial (loading) dose—but smaller maintenance dose might be required in these patients.

Page 76: Neuromuscular blocking agents
Page 77: Neuromuscular blocking agents
Page 78: Neuromuscular blocking agents

ATRACURIUM• Has a quaternary group.• Benzylisoquinoline structure is responsible

for its its unique method of degradaton.• It undergoes hofmann elimination and

ester hydrolysis.• Its metabolism is independent of hepatic

and renal function.

Page 79: Neuromuscular blocking agents

Dosage & Storage

Page 80: Neuromuscular blocking agents

Side Effects & Clinical Considerations

Page 81: Neuromuscular blocking agents
Page 82: Neuromuscular blocking agents
Page 83: Neuromuscular blocking agents
Page 84: Neuromuscular blocking agents

CISATRACURIUM• It is a stereoisomer of atracurium.• Four times more potent than atracurium.• It undergoes hofmann elimination like atracurium but ester

hydrolysis dose not occur.• It dose not produce the histamine and laudanosine

production is 5 times lesser than atracurium.• Metabolism and elemination are independent of hepatic and

renal failure.• Does not alter heart rate or blood pressure,not alter heart rate or blood pressure, nor does it

produce autonomic effects.• Cisatracurium shares with atracurium the…

– production of laudanosine,laudanosine, – pH and temperature sensitivitypH and temperature sensitivity & chemical

incompatibility. •

Page 85: Neuromuscular blocking agents
Page 86: Neuromuscular blocking agents

PANCURONIUM

Page 87: Neuromuscular blocking agents
Page 88: Neuromuscular blocking agents
Page 89: Neuromuscular blocking agents

Side Effects & Clinical Considerations

Page 90: Neuromuscular blocking agents
Page 91: Neuromuscular blocking agents

VECURONIUM

Page 92: Neuromuscular blocking agents
Page 93: Neuromuscular blocking agents
Page 94: Neuromuscular blocking agents

ROCURONIUM

Page 95: Neuromuscular blocking agents
Page 96: Neuromuscular blocking agents
Page 97: Neuromuscular blocking agents
Page 98: Neuromuscular blocking agents

NEWER MUSCLE

RELAXANTS

Page 99: Neuromuscular blocking agents

Gantacurium

Page 100: Neuromuscular blocking agents
Page 101: Neuromuscular blocking agents

AV002 (CW002)

Page 102: Neuromuscular blocking agents
Page 103: Neuromuscular blocking agents
Page 104: Neuromuscular blocking agents

OTHER RELAXANTS(Historical interest)

Page 105: Neuromuscular blocking agents
Page 106: Neuromuscular blocking agents
Page 107: Neuromuscular blocking agents
Page 108: Neuromuscular blocking agents

References:• Miller’s anaesthesia(7th edition)• Clinical anaesthesiology(5th edition):Morgan• Essentials of medical Pharmacoly:K.D.Tripathy• Short Text book of anaesthesia: Ajay Yadav• E-Books

Page 109: Neuromuscular blocking agents